BioSpace News Archive

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European patent office has granted the divisional patent application titled “Formulations and Metho

Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern time. A live audio webcast of

Bicycle Therapeutics plc today announced that management will participate in a panel discussion on bispecifics at the Canaccord Genuity Horizons in Oncology Conference on Wednesday, April 8, 2020 at 10:15 a.m. ET. The conference will be hel

April 6, 2020 11:00 UTC Appointment enables global development and commercialization planning for AlloVir’s growing pipeline of allogeneic, off-the-shelf, virus-specific T cell therapies CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that Ugo Capolino Perlingieri has been appointed to the newly created position of General Manager of Europe and Middle East operations. In this role, he will be responsible for

Getinge, the world market leader in advanced ventilators for intensive care units, is announcing yet another ramp-up in production capacity, to 26,000 ventilators in 2020. The increase equals a growth of 160% compared to 2019, when 10,000 ventilators were produced. The demand for advanced ventilators for the intensive care

NanoMosaic L.L.C. – the leading company in protein and nucleic acid detection leveraging the power of nanoneedles for ultra-sensitive, wide dynamic range, multiplexed protein detection has announced a collaboration with Massachusetts General Hospital (MGH) in order to develop a new method for the prognostics and treatment of COVID-19 patients.

Windtree Therapeutics, Inc. (OTCQB: WINT), today announced the presentation of a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned website, www.aprea.com.

Catalyst Biosciences, Inc. today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a pivotal Phase 3 trial design for Marzeptacog alfa (activated) – MarzAA. The open-label trial will evaluate the effi

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months GSK to make equity investment of $250 million in Vir LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced